Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OMER Omeros

Trading 08-13 11:22:28 EDT

16.43

+2.72

+19.84%

High18.13	Low16.27	Vol7.11M
Open16.87	D1 Closing13.71	Amplitude13.57%
Mkt Cap1.19B	Tradable Cap1.12B	Total Shares72.38M
T/O122.92M	T/O Rate10.42%	Tradable Shares68.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"Omeros","latestPrice":16.43,"timestamp":1786634547183,"preClose":13.71,"halted":0,"volume":7111698,"delay":0,"changeRate":0.19839533187454403,"floatShares":68245659,"shares":72375355,"eps":1.20879,"marketStatus":"Trading","change":2.72,"latestTime":"08-13 11:22:28 EDT","open":16.868,"high":18.13,"low":16.27,"amount":122916042.24411601,"amplitude":0.135667,"askPrice":16.47,"askSize":400,"bidPrice":16.41,"bidSize":609,"shortable":3,"etf":0,"ttmEps":1.20879,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786651200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":13.71,"preHourTrading":{"tag":"盘前","latestPrice":16.57,"preClose":13.71,"latestTime":"09:29 EDT","volume":202428,"amount":3321935.3823120003,"timestamp":1786627799999,"change":2.86,"changeRate":0.208607,"amplitude":0.113764},"postHourTrading":{"tag":"盘后","latestPrice":16.2,"preClose":13.71,"latestTime":"19:59 EDT","volume":1491894,"amount":24123969.2832,"timestamp":1786579166464,"change":2.49,"changeRate":0.181619,"amplitude":0.258264},"volumeRatio":13.741299,"impliedVol":0.731,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/OMER","defaultTab":"news","newsList":[{"id":"2659315736","title":"Biofrontera Q2 Revenue Rises on Higher Volume, Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315736","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315736?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:01","pubTimestamp":1786626085,"startTime":"0","endTime":"0","summary":"Biofrontera Q2 revenue rises on higher volume, pricingOverviewU.S. biopharmaceutical firm's Q2 revenue grew 33% yr/yr, driven by higher unit volume and pricingNet loss for Q2 narrowed to $0.6 mln from","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4139","PTHS","BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151875","title":"CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151875?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:42","pubTimestamp":1786621337,"startTime":"0","endTime":"0","summary":"CorMedix beatsQ2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidanceOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsEPS for Q2 beat analyst expectationsC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","LEGN","BK4139","BK4585","MEMS","BK4505","BK4007","CANC","MEDI","CRMD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659915189","title":"Karyopharm Q2 Revenue Falls as License Revenue Drops; Expects Funds to Last into September","url":"https://stock-news.laohu8.com/highlight/detail?id=2659915189","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659915189?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:41","pubTimestamp":1786621315,"startTime":"0","endTime":"0","summary":"Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into SeptemberOverviewCancer drug developer's Q2 revenue declined yr/yr as license and other revenue fellU.S. XPOVIO net pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TXMD","OMER","BK4139","KPTI","BK4007","BK4505","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159826","title":"Pelthos Therapeutics Q2 Revenue Rises on Zelsuvmi Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159826","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159826?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:20","pubTimestamp":1786620006,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoptionOverviewU.S. biopharmaceutical firm's Q2 net product revenue grew 45% quarter-over-quarterNet loss for Q2 narrowed compared to Q1, adjusted EB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER","BK4139","PTHS","LQDA","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659515537","title":"Omeros Maintained at Buy as Strong YARTEMLEA Launch and Reduced C5 Competition Support Unchanged $33 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2659515537","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659515537?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:36","pubTimestamp":1786617413,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Omeros today and set a price target of $33.00. Brandon Folkes has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/omeros-maintained-at-buy-as-strong-yartemlea-launch-and-reduced-c5-competition-support-unchanged-33-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/omeros-maintained-at-buy-as-strong-yartemlea-launch-and-reduced-c5-competition-support-unchanged-33-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659362153","title":"Omeros Jumps on Surprise Quarterly Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2659362153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659362153?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:12","pubTimestamp":1786615957,"startTime":"0","endTime":"0","summary":"BUZZ-Omeros jumps on surprise quarterly profit** Shares of drugmaker OmerosOMER.Orise 17% to $16.05 premarket** Co reports Q2 profit of 15 cents/shr vs analysts' average estimate of a loss of 27 cents/shr, according to LSEG data** OMER's Q2 revenue of $28.5 million beats analysts' expectation of $12.7 million on strong sales of its drug Yartemlea** Yartemlea is used to treat a rare but severe medical complication where blood clots form in the small blood vessels, usually after a bone marrow or stem cell transplant** Up to last close, stock down 20.2% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A0SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659613078","title":"Omeros Swings to Q2 Adjusted Earnings; Shares up","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613078","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659613078?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:38","pubTimestamp":1786613935,"startTime":"0","endTime":"0","summary":"Omeros  reported Wednesday Q2 adjusted net earnings of $0.02 per diluted share, swinging from a loss of $0.57 a year earlier.Two analysts polled by FactSet expected a loss of $0.30.Revenue for the quarter ended June 30 was $28.5 million, compared with nil a year ago.Three analysts surveyed by FactSet expected $12.7 million.Shares of the company were up more than 16.7% in Thursday's premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659858021","title":"Omeros Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659858021","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659858021?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:37","pubTimestamp":1786570665,"startTime":"0","endTime":"0","summary":"Omeros Corporation reports results for the quarter ended June 30 - Earnings SummaryOmeros CorporationOMER.OQreported quarterly adjusted earnings of 15 cents per share for the quarter ended June 30, hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N449290:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860185","title":"Omeros Q2 2026 Earnings: YARTEMLEA Drives Operating Break-Even","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860185","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659860185?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:17","pubTimestamp":1786565867,"startTime":"0","endTime":"0","summary":"Omeros reported Q2 2026 net product sales of $28.5 million, up from zero a year earlier, as YARTEMLEA gross revenue reached $32.2 million and rose 190% from Q1. GAAP net income was $13.2 million, with basic EPS of $0.18, but included an $11.5 million non-cash fair-value gain; non-GAAP adjusted net income was $1.8 million. Operations generated $4.1 million of cash, while June-end cash and short-term investments totaled $132.0 million before a $60.2 million convertible-note repurchase completed in July.","market":"nz","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock13.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock13.jpg"],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262100429-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907012","title":"Omeros Q2 Yartemlea Net Revenue Jumps 190%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907012","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907012?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:10","pubTimestamp":1786565437,"startTime":"0","endTime":"0","summary":"Omeros Q2 YARTEMLEA net revenue jumps 190%OverviewBiotechnology firm's Q2 net revenue from YARTEMLEA surged 190% quarter-over-quarterQ2 net income was $13.2 mln; non-GAAP adjusted net income reached $","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44910Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4139","BBIO","BK4585","LQDA","BK4505","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659490729","title":"Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659490729","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659490729?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:06","pubTimestamp":1786565177,"startTime":"0","endTime":"0","summary":"Omeros (NASDAQ:OMER) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.27) by 107.41 percent. This is a 104.65 percent increase over losses of $(0.43) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61157741/omeros-q2-adj-eps-0-02-beats-0-27-estimate-sales-28-529m-beat-12-700m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907502","title":"Omeros Corporation Q2 EPS USD 0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907502?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:02","pubTimestamp":1786564921,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXD7M7FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658954419","title":"Omeros Corporation Expected to Post a Loss of 27 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658954419","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658954419?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:04","pubTimestamp":1786395845,"startTime":"0","endTime":"0","summary":"Omeros Corporation <OMER.OQ> expected to post a loss of27cents a share - Earnings PreviewOmeros CorporationOMER.OQOMER.Ois expected to  show a rise in quarterly revenue when it reports  results on Aug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N447211:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936851","title":"Press Release: Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936851","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936851?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:06","pubTimestamp":1786363560,"startTime":"0","endTime":"0","summary":"SEATTLE--(BUSINESS WIRE)--August 10, 2026--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4007","R","OMER","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935405","title":"Omeros to Report Q2 Results, Host Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935405?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:02","pubTimestamp":1786363366,"startTime":"0","endTime":"0","summary":"Omeros to report Q2 results, host earnings callOmeros schedules release of Q2 2026 financial results for Aug. 12, 2026, following the market close.Management sets an earnings conference call, webcast ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLc1r8mD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656137901","title":"Omeros grants new technology add-on payment status to Yartemlea","url":"https://stock-news.laohu8.com/highlight/detail?id=2656137901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656137901?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:41","pubTimestamp":1785760901,"startTime":"0","endTime":"0","summary":"Omeros (OMER) Corporation announced that the Centers for Medicare & Medicaid Services, CMS, has granted New Technology Add-On Payment, NTAP, status...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-grants-new-technology-add-on-payment-status-to-yartemlea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-grants-new-technology-add-on-payment-status-to-yartemlea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNGR","BK4007","OMER","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379188","title":"Omeros Corp - Eligible Hospitals to Receive Additional Medicare Reimbursement for Yartemlea from October 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379188?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:32","pubTimestamp":1785760329,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400QC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379186","title":"Omeros Corp - CMS Grants Ntap Status for Yartemlea Under Fy2027 Ipps Final Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379186?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:32","pubTimestamp":1785760329,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049752","title":"Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Omeros (OMER)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654049752?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:40","pubTimestamp":1785166806,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX) and Omeros (OMER). Argenx Se (ARG...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-argenx-se-argx-and-omeros-omer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-argenx-se-argx-and-omeros-omer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","IE00BFTCPJ56.SGD","LABU","TBXU","IE00BJJMRZ35.SGD","LU1983260115.SGD","LU0128526141.USD","BK4585","BK4505","IE00B4R5TH58.HKD","LU0320765992.SGD","IBB","ARGX","OMER","IE00B2B36J28.USD","FMED","IE0034235188.USD","BK4581","XBI","BK4137","XLV","BK4588","BK4139","LU2324357040.USD","IE0009355771.USD","LU0889565916.HKD","BK4007","LU0029874061.USD","LU0109394709.USD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049892","title":"Omeros Buy Rating Reiterated as Ultomiris Setback Eases Competitive Risk; $33 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654049892?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:35","pubTimestamp":1785162936,"startTime":"0","endTime":"0","summary":"Omeros, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/omeros-buy-rating-reiterated-as-ultomiris-setback-eases-competitive-risk-33-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/omeros-buy-rating-reiterated-as-ultomiris-setback-eases-competitive-risk-33-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":0.0838},{"period":"1month","weight":0.3696},{"period":"3month","weight":0.0324},{"period":"6month","weight":0.1728},{"period":"1year","weight":2.2799},{"period":"ytd","weight":-0.2017}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":-0.012739},{"month":2,"riseRate":0.588235,"avgChangeRate":0.056959},{"month":3,"riseRate":0.588235,"avgChangeRate":0.084424},{"month":4,"riseRate":0.411765,"avgChangeRate":-0.00729},{"month":5,"riseRate":0.352941,"avgChangeRate":-0.04488},{"month":6,"riseRate":0.294118,"avgChangeRate":0.025891},{"month":7,"riseRate":0.470588,"avgChangeRate":0.076019},{"month":8,"riseRate":0.352941,"avgChangeRate":-0.018283},{"month":9,"riseRate":0.3125,"avgChangeRate":-0.001727},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042054},{"month":11,"riseRate":0.647059,"avgChangeRate":0.236058},{"month":12,"riseRate":0.529412,"avgChangeRate":0.065706}],"exchange":"NASDAQ","name":"Omeros","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Omeros,OMER,Omeros股票,Omeros股票老虎,Omeros股票老虎国际,Omeros行情,Omeros股票行情,Omeros股价,Omeros股市,Omeros股票价格,Omeros股票交易,Omeros股票购买,Omeros股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction